rezpegaldesleukin
Protein / enzyme therapeutic
Also known as NKTR-358, LY3471851
Evidence outlook · registrational
Atopic Dermatitis: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-05. The sponsor reported topline results of a Phase 2 study on 2026-02-10 (Phase 2b REZOLVE-AD of rezpegaldesleukin: 36-week maintenance period results); that is not the registrational readout.
Also in development:Alopecia Areata · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ZENITH AD-1 NCT07690371 · Moderate-to-Severe Atopic Dermatitis Registry: NCT07690371 | 3 | US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24 (Week 0 and Week 24); Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24 (Week 0 and Week 24); Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75) (Week 0 and Week 24) 2028-05 | In progress: results expected 1 May 2028 | not yet graded | link ↗ |
View 1 more trial
ZENITH AD-2 NCT07711418 · Moderate-to-Severe Atopic Dermatitis Registry: NCT07711418 | 3 | US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24 (Week 0 and Week 24); Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24 (Week 0 and Week 24); Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75) (Week 0 and Week 24) 2028-06 | In progress: results expected 1 Jun 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Alopecia Areata: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rezpegaldesleukin: this drug | Phase 2 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13). | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | Partial signal | NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison. |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow rezpegaldesleukin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (3)
May 2028 (2)
June 2028 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent